BREZTRI AEROSPHERE is indicated for the long-term maintenance treatment to reduce exacerbations of COPD and treat airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema, who are not adequately treated by a combination of an ICS/LABA or a combination of LAMA/LABA.

Click here for additional safety information and for a link to the product monograph discussing:

• Relevant warnings and precautions regarding risk of serious asthma-related events, deterioration of disease, excessive use with other LAMA and LABA products, anticholinergic activity, cardiovascular effects, driving and operating machinery, candidiasis, risk of systemic effects, hypercorticism, adrenal suppression, adrenal insufficiency in patients transferred from systemic steroid, patients with symptomatic prostatic hyperplasia, glaucoma, convulsive disorders, thyrotoxicosis, sensitivity to sympathomimetic amines, severe hepatic impairment/hepatic disease, or urinary retention, systemic eosinophilic conditions (in rare cases), susceptibility or decreased resistance to infections, monitoring, paradoxical bronchospasm, increased risk of pneumonia, pregnant and nursing women, and geriatrics.
• Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

The Product Monograph is also available by calling AstraZeneca Canada at 1-800-668-6000.

COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroid; LABA: long-acting beta2-adrenergic agonist; LAMA: long-acting muscarinic antagonist.

Reference:

1. BREZTRI AEROSPHERE Product Monograph. AstraZeneca Canada Inc.